{"id":68015,"date":"2026-11-01T18:48:47","date_gmt":"2026-11-01T13:18:47","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68015"},"modified":"2026-11-01T18:48:49","modified_gmt":"2026-11-01T13:18:49","slug":"new-series-of-interactive-cardiology-mcqs-20","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/","title":{"rendered":"New Series of Interactive Cardiology MCQs 20"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n\n\n<!-- Cardiology MCQs Part 20 (Full 25 Questions) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = {\n    corePlugins: { preflight: false }\n  }\n<\/script>\n\n<div id=\"mcq20-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-rose-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <!-- Background Accents -->\n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-rose-500 via-red-900 to-slate-950\"><\/div>\n  \n  <!-- Header Banner -->\n  <div class=\"relative text-center pb-6 border-b border-solid border-rose-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-rose-500 via-red-600 to-pink-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \ud83c\udfc6 Advanced Cardiology Series &#8211; Milestone Part 20\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-rose-300 via-red-400 to-pink-400 m-0\">\n      Interactive Cardiology MCQs #20\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Clinical, Hemodynamics, EP &amp; Structural Masterclass\n    <\/p>\n  <\/div>\n\n  <!-- Real-Time Floating Scoreboard -->\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-rose-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83c\udfaf<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-rose-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-red-300 flex items-center gap-1\">\n          <span id=\"mcq20-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq20-progress-bar\" class=\"bg-gradient-to-r from-rose-500 to-red-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-red-300\"><span id=\"mcq20-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <!-- Quiz Questions Container -->\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When evaluating the severity of Mitral Regurgitation (MR) via color flow Doppler echocardiography, what measurement of the vena contracta width is the standard cutoff indicative of SEVERE mitral regurgitation?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A vena contracta of &lt; 0.3 cm indicates mild MR. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">A) Vena contracta width &gt;= 0.3 cm.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"0.5 cm falls into the moderate category (0.3 to 0.69 cm). Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">B) Vena contracta width &gt;= 0.5 cm.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The vena contracta is the narrowest neck of the regurgitant jet. A vena contracta width of &gt;= 0.7 cm (7 mm) is highly specific for severe mitral regurgitation. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">C) Vena contracta width &gt;= 0.7 cm.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A 1.0 cm cutoff is far too high; waiting for this degree of severity would miss many cases of severe MR. Reference: 2017 ASE Guidelines for Noninvasive Evaluation of Native Valvular Regurgitation.\">D) Vena contracta width &gt;= 1.0 cm.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Brugada syndrome is a genetic channelopathy carrying a high risk of sudden cardiac death. What is the classic electrocardiographic definition of the Type 1 (diagnostic) Brugada pattern?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Saddleback ST elevation describes the Type 2 or Type 3 Brugada pattern, which requires drug challenge to confirm diagnosis. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">A) &#8216;Saddleback&#8217; ST-segment elevation &gt;= 1 mm in leads V1-V3 followed by a positive T wave.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The diagnostic Type 1 Brugada pattern is defined as a coved (convex) ST-segment elevation &gt;= 2 mm (0.2 mV) in at least one right precordial lead (V1, V2) positioned in the 2nd, 3rd, or 4th intercostal space, followed by a symmetric negative T wave. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">B) A coved ST-segment elevation &gt;= 2 mm in &gt;= 1 right precordial lead (V1-V2) followed by a negative T wave.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diffuse ST elevation with PR depression is classic for acute pericarditis. Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">C) Diffuse, concave ST-segment elevation with PR segment depression in all precordial leads.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An epsilon wave is the classic finding in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Reference: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias.\">D) A terminal notch in the QRS complex (epsilon wave) in leads V1-V3.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          SGLT2 inhibitors (e.g., Dapagliflozin, Empagliflozin) have become foundational therapy for both HFrEF and HFpEF. Where in the nephron do these medications primarily exert their pharmacologic effect to induce glycosuria and natriuresis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"SGLT2 (Sodium-Glucose Cotransporter 2) is almost exclusively located in the proximal convoluted tubule of the nephron. It is responsible for reabsorbing approximately 90% of the filtered glucose. Inhibiting it here causes profound glycosuria, osmotic diuresis, and natriuresis, contributing to its heart failure benefits. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">A) The Proximal Convoluted Tubule.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The thick ascending limb of the loop of Henle is the site of action for Loop Diuretics (e.g., Furosemide). Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">B) The Thick Ascending Limb of the Loop of Henle.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The distal convoluted tubule is the site of action for Thiazide diuretics. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">C) The Distal Convoluted Tubule.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The collecting duct is the primary site of action for Mineralocorticoid Receptor Antagonists (e.g., Spironolactone). Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">D) The Cortical Collecting Duct.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During a bedside echocardiogram on a hypotensive patient presenting with acute dyspnea, the physician identifies &#8216;McConnell&#8217;s sign.&#8217; What specific wall motion abnormality does this describe, and what is the presumed diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diffuse apical ballooning with basal hyperkinesis describes Takotsubo Cardiomyopathy. Reference: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.\">A) Diffuse apical ballooning of the left ventricle; diagnostic of Takotsubo Cardiomyopathy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Asymmetric septal hypertrophy is a hallmark of Hypertrophic Cardiomyopathy (HOCM). Reference: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.\">B) Asymmetric septal hypertrophy with systolic anterior motion of the mitral valve; diagnostic of HOCM.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"McConnell's sign is a distinct regional wall motion abnormality defined by severe akinesia (lack of movement) of the right ventricular mid-free wall, with complete sparing (hyperkinesia) of the RV apex. It is highly specific for acute right ventricular pressure overload, classically caused by a massive Acute Pulmonary Embolism. Reference: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.\">C) Akinesia of the right ventricular mid-free wall with hyperkinesia of the RV apex; highly specific for Acute Pulmonary Embolism.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Paradoxical septal bounce is typically seen in constrictive pericarditis or severe RV volume overload. Reference: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.\">D) Paradoxical septal motion (&#8216;septal bounce&#8217;) during early diastole; highly specific for Constrictive Pericarditis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient presenting with recent episodes of chest pain at rest is now pain-free. Their ECG shows deeply and symmetrically inverted T waves in leads V2 and V3 without Q waves. What is this clinical entity, and what does it herald?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"De Winter's T waves consist of upsloping ST depression leading into tall, prominent, symmetric T waves, not inverted T waves. Reference: Chou's Electrocardiography in Clinical Practice.\">A) De Winter&#8217;s syndrome; indicating acute proximal RCA occlusion.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"This represents Wellens' Syndrome (Type B pattern). It occurs during the pain-free interval after an episode of ischemia and indicates a critical, high-grade stenosis of the proximal Left Anterior Descending (LAD) artery. Without urgent revascularization, these patients are at extremely high risk for an imminent, massive anterior wall myocardial infarction. Reference: Chou's Electrocardiography in Clinical Practice.\">B) Wellens&#8217; syndrome; indicating critical stenosis of the proximal Left Anterior Descending (LAD) artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Brugada pattern involves coved ST elevations in V1-V2, not symmetrically inverted T waves alone in V2-V3. Reference: Chou's Electrocardiography in Clinical Practice.\">C) Brugada syndrome; indicating a genetic sodium channelopathy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Posterior MIs show ST depression and tall R waves in V1-V3, often with upright T waves, not deeply inverted T waves. Reference: Chou's Electrocardiography in Clinical Practice.\">D) Acute posterior STEMI; indicating occlusion of the circumflex artery.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Tetralogy of Fallot (TOF) features four classic anatomical abnormalities. However, the clinical severity and degree of cyanosis (the presence of &#8220;Tet spells&#8221;) are almost entirely determined by the severity of which specific component?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The VSD in TOF is almost always large and unrestrictive; it does not dictate the degree of right-to-left shunting alone. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">A) The size of the Ventricular Septal Defect (VSD).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The overriding aorta is a structural result of septal malalignment but does not dictate flow dynamics as much as RVOT obstruction. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">B) The degree of aortic override.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The primary determinant of hemodynamics and clinical severity in TOF is the degree of Right Ventricular Outflow Tract (RVOT) obstruction (infundibular pulmonary stenosis). Increased RVOT resistance forces deoxygenated blood from the RV across the VSD into the aorta (right-to-left shunt), leading to cyanosis. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">C) The degree of Right Ventricular Outflow Tract (RVOT) obstruction.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"RVH is a secondary compensatory consequence of the RVOT obstruction, not the primary driver of cyanosis. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">D) The thickness of Right Ventricular Hypertrophy (RVH).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When comparing oral P2Y12 inhibitors used in Acute Coronary Syndromes, how does the pharmacologic mechanism of Ticagrelor fundamentally differ from Clopidogrel and Prasugrel?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Clopidogrel and Prasugrel are prodrugs requiring hepatic activation; Ticagrelor is an active drug. Reference: 2023 ESC Guidelines for the management of ACS.\">A) Ticagrelor is a prodrug requiring hepatic CYP2C19 activation, whereas Clopidogrel is an active molecule.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Clopidogrel and Prasugrel are thienopyridines that irreversibly bind the P2Y12 receptor and require hepatic metabolism (prodrugs). In contrast, Ticagrelor is a cyclopentyltriazolopyrimidine (CPTP) that is an active drug (no hepatic activation needed) and acts as a REVERSIBLE, non-competitive allosteric antagonist at the P2Y12 receptor. Reference: 2023 ESC Guidelines for the management of ACS.\">B) Ticagrelor is a reversible, active drug that does not require hepatic biotransformation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ticagrelor is reversible; Clopidogrel and Prasugrel are irreversible. Reference: 2023 ESC Guidelines for the management of ACS.\">C) Ticagrelor irreversibly binds the P2Y12 receptor, whereas Clopidogrel binds reversibly.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ticagrelor blocks the P2Y12 ADP receptor, not the PAR-1 thrombin receptor (which is targeted by Vorapaxar). Reference: 2023 ESC Guidelines for the management of ACS.\">D) Ticagrelor primarily inhibits the PAR-1 thrombin receptor rather than the ADP receptor.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with a normal ejection fraction (LVEF 60%) is being evaluated for aortic stenosis. Echocardiography reveals a calculated Aortic Valve Area (AVA) of 0.8 cm\u00b2, but the mean transvalvular gradient is only 28 mmHg. What specific diagnostic entity does this hemodynamics profile suggest?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Classical Low-Flow, Low-Gradient AS occurs in the setting of severe LV systolic dysfunction (LVEF &lt; 50%). Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">A) Classical Low-Flow, Low-Gradient Severe Aortic Stenosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Normal flow, high-gradient AS would feature a mean gradient &gt;= 40 mmHg. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">B) Normal-Flow, High-Gradient Severe Aortic Stenosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"This represents Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis. It occurs when severe AS (AVA &lt; 1.0 cm\u00b2) is present with a low gradient (&lt; 40 mmHg) despite a PRESERVED LVEF (&gt;= 50%). It is 'paradoxical' because a small LV cavity with severe concentric hypertrophy restricts filling, causing a low stroke volume index (&lt;= 35 mL\/m\u00b2), preventing the generation of a high transvalvular gradient. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">C) Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The AVA &lt; 1.0 cm\u00b2 points to severe obstruction, so simply calling it moderate based on gradient ignores the low-flow state. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">D) Uncomplicated Moderate Aortic Stenosis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A young patient presents with a hemodynamically stable sustained ventricular tachycardia. The ECG shows a Right Bundle Branch Block (RBBB) morphology with a marked Superior Axis (Left Axis Deviation). The arrhythmia terminates rapidly with intravenous Verapamil. Where does this tachycardia classically originate?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"RVOT VT presents with a Left Bundle Branch Block (LBBB) morphology and an inferior axis. Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.\">A) Right Ventricular Outflow Tract (RVOT).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"This describes Idiopathic Left Ventricular Tachycardia (ILVT), also known as Fascicular VT or Belhassen VT. The most common form originates from the Left Posterior Fascicle. Because the impulse originates in the LV, it creates an RBBB pattern. Because it originates infero-posteriorly, it travels superiorly, creating a Left Axis Deviation. It is classically highly sensitive to Verapamil. Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.\">B) Left Posterior Fascicle.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"VT from the left anterior fascicle would present with an RBBB morphology but a Right Axis Deviation (inferior axis). Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.\">C) Left Anterior Fascicle.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"LVOT VT typically shows an LBBB (or atypical RBBB) with a steeply inferior axis. Reference: 2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.\">D) Left Ventricular Outflow Tract (LVOT).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When differentiating acute viral pericarditis from an acute STEMI on a 12-lead ECG, which specific PR segment finding is highly characteristic of acute pericarditis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This represents varying degrees of AV block, not a classic ischemic or pericarditic change. Reference: Chou's Electrocardiography in Clinical Practice.\">A) Progressive lengthening of the PR interval.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The PR segment is typically DEPRESSED in V5\/V6 in pericarditis. Reference: Chou's Electrocardiography in Clinical Practice.\">B) PR segment elevation in leads II, V5, and V6.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Acute pericarditis causes a diffuse subepicardial atrial injury current. This uniquely presents as PR segment ELEVATION in lead aVR, accompanied by reciprocal PR segment DEPRESSION in most other leads (especially II, aVF, and V4-V6). Reference: Chou's Electrocardiography in Clinical Practice.\">C) PR segment elevation in lead aVR, with PR segment depression in leads II and V5-V6.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"PR depression in aVR would be the opposite of the classic finding. Reference: Chou's Electrocardiography in Clinical Practice.\">D) PR segment depression strictly isolated to lead aVR.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Biologic therapies like Alirocumab and Evolocumab are highly potent lipid-lowering agents. What is their exact mechanism of action at the cellular level?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"These drugs are monoclonal antibodies that inhibit PCSK9 (Proprotein Convertase Subtilisin\/Kexin type 9). Normally, PCSK9 binds to LDL receptors and marks them for lysosomal degradation. By inhibiting PCSK9, these drugs prevent the destruction of LDL receptors, allowing them to recycle to the hepatocyte surface to continuously clear LDL from the blood. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">A) They inhibit PCSK9, preventing the lysosomal degradation of hepatic LDL receptors.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of Inclisiran (a small interfering RNA), not the monoclonal antibodies. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">B) They silence PCSK9 mRNA translation via small interfering RNA (siRNA) interference.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Bempedoic acid inhibits ATP citrate lyase. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">C) They inhibit ATP citrate lyase in the cholesterol synthesis pathway.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ezetimibe inhibits NPC1L1. Reference: 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol.\">D) They block intestinal cholesterol absorption via the NPC1L1 transporter.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with a known history of Ebstein&#8217;s anomaly presents with palpitations. A resting 12-lead ECG is obtained. Which specific arrhythmia syndrome is classically associated with this congenital defect in up to 20% of cases?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Brugada is a channelopathy not structurally associated with Ebstein's anomaly. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">A) Brugada Syndrome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While bundle branch blocks (specifically RBBB) are common in Ebstein's, true congenital Long QT syndrome is a distinct channelopathy. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">B) Congenital Long QT Syndrome Type 1.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Ebstein's anomaly (apical displacement of the tricuspid valve creating an 'atrialized' right ventricle) is highly associated with accessory electrical pathways. Approximately 20% of patients have Wolff-Parkinson-White (WPW) syndrome, and the accessory pathways are almost exclusively right-sided, leading to frequent AVRTs. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">C) Wolff-Parkinson-White (WPW) Syndrome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Catecholaminergic polymorphic VT is related to ryanodine receptor mutations, not structurally linked to Ebstein's. Reference: 2020 ESC Guidelines for the management of adult congenital heart disease.\">D) Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          While Digoxin toxicity can manifest as almost any cardiac arrhythmia, which specific dysrhythmia is considered the most classic and characteristic hallmark of digitalis intoxication?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Sinus tach is uncommon because digoxin typically increases vagal tone, slowing the sinus rate. Reference: Chou's Electrocardiography in Clinical Practice.\">A) Sinus Tachycardia with first-degree AV block.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Digoxin toxicity uniquely produces a combination of INCREASED atrial automaticity (due to intracellular calcium overload) and DECREASED AV nodal conduction (due to enhanced vagal tone). This dual effect classically manifests as Atrial Tachycardia with variable AV block (e.g., 2:1 block). Reference: Chou's Electrocardiography in Clinical Practice.\">B) Atrial Tachycardia with variable AV block.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Torsades is classically caused by Class IA\/III antiarrhythmics that prolong the QT interval; digoxin actually shortens the QT interval. Reference: Chou's Electrocardiography in Clinical Practice.\">C) Torsades de Pointes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Digoxin generally slows the ventricular response in AFib, and while severe toxicity can cause slow junctional rhythms, fast chaotic AFib is not the hallmark of toxicity. Reference: Chou's Electrocardiography in Clinical Practice.\">D) Rapid, chaotic Atrial Fibrillation with pre-excitation.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with HER2-positive breast cancer is undergoing treatment with Trastuzumab (Herceptin) and develops a reduced Left Ventricular Ejection Fraction (LVEF). Which of the following accurately describes Trastuzumab-induced cardiotoxicity (Type II)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This perfectly describes Anthracycline (Type I) toxicity, not Trastuzumab. Reference: 2022 ESC Guidelines on cardio-oncology.\">A) It is strictly dose-dependent and causes irreversible myocardial necrosis and fibrosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Trastuzumab causes Type II cardiotoxicity. Unlike anthracyclines, it is NOT strictly dose-dependent, does not typically cause ultrastructural myocardial necrosis\/fibrosis, and the LV dysfunction is largely reversible upon holding the drug and initiating standard heart failure therapy. Reference: 2022 ESC Guidelines on cardio-oncology.\">B) It is not strictly dose-dependent, lacks typical ultrastructural destruction, and is largely reversible upon drug cessation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Immune checkpoint inhibitors cause fulminant myocarditis. Reference: 2022 ESC Guidelines on cardio-oncology.\">C) It presents as a fulminant T-cell mediated myocarditis requiring high-dose steroids.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"5-Fluorouracil (5-FU) classically causes acute coronary vasospasm. Reference: 2022 ESC Guidelines on cardio-oncology.\">D) It causes acute, severe coronary vasospasm during the infusion leading to STEMI.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During a peripheral arterial evaluation, an Ankle-Brachial Index (ABI) is calculated to be 1.55. What does an ABI of this value signify?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A normal resting ABI is between 1.00 and 1.40. Reference: 2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease.\">A) Normal, healthy arterial flow.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Mild to moderate PAD is indicated by an ABI of 0.41 to 0.90. Reference: 2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease.\">B) Mild to moderate Peripheral Artery Disease (PAD).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Severe PAD is indicated by an ABI &lt;= 0.40. Reference: 2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease.\">C) Severe Peripheral Artery Disease with critical limb ischemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"An ABI &gt; 1.40 indicates severely calcified, non-compressible arteries (often M\u00f6nckeberg's medial calcific sclerosis), rendering the ABI test falsely elevated and unreliable for ruling out PAD. This is frequently seen in advanced diabetes and end-stage renal disease. A toe-brachial index (TBI) should be performed instead. Reference: 2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease.\">D) Non-compressible, heavily calcified arteries, rendering the test unreliable.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with metastatic neuroendocrine tumors develops severe right-sided heart failure. Echocardiography shows retracted, immobile tricuspid valve leaflets with severe regurgitation. Why does Carcinoid Heart Disease predominantly spare the left-sided heart valves?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Carcinoid syndrome releases high levels of vasoactive substances (primarily serotonin) into the venous circulation, damaging the right heart valves. The left heart is spared because serotonin is effectively metabolized and cleared by monoamine oxidase (MAO) as blood passes through the pulmonary vascular bed. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">A) Vasoactive substances (e.g., serotonin) are inactivated by monoamine oxidase as blood passes through the lungs.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Serotonin receptors are present throughout the cardiovascular system, but the hormone never reaches the left side in high concentrations. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">B) Left-sided valves genetically lack the 5-HT2B serotonin receptors required for plaque formation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While left-sided pressures are higher, the primary mechanism of sparing is metabolic clearance, not mechanical stress. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">C) The high systolic pressure in the left heart mechanically prevents the deposition of carcinoid plaques.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Most carcinoid tumors drain into the portal vein and are metabolized by the liver, but once liver metastases occur, serotonin enters the hepatic veins (right heart) directly. Reference: 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease.\">D) The hepatic circulation selectively shunts carcinoid hormones away from the left atrium.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with a dual-chamber permanent pacemaker (DDD mode) requires urgent surgery with electrocautery. A clinical magnet is placed securely over the pacemaker generator. What is the expected physiological response of a standard pacemaker to magnet application?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A magnet does not turn the device off; it ensures pacing continues by ignoring external noise. Reference: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.\">A) It completely disables all pacing and sensing functions (turns the device off).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Applying a magnet to an ICD disables tachy-therapies (shocks), but for a standalone pacemaker, it changes the pacing mode. Reference: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.\">B) It disables anti-tachycardia pacing (ATP) but leaves sensing completely intact.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Placing a magnet over a standard pacemaker closes a reed switch, converting the device to an ASYNCHRONOUS pacing mode (DOO or VOO) at a fixed magnet rate. This disables 'sensing' so that the device will not inappropriately inhibit pacing if it mistakes surgical electrocautery noise for native heartbeats. Reference: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.\">C) It converts the device to an asynchronous pacing mode (e.g., DOO or VOO), ignoring native sensing.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pacing output energy (voltage) is not typically maximized; the mode just becomes fixed\/asynchronous. Reference: 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.\">D) It maximizes the pacing voltage output to 5.0V while maintaining normal DDD sensing.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Four days after suffering an acute Inferior STEMI, a patient suddenly develops cardiogenic shock and a loud new holosystolic murmur at the apex. Echocardiography confirms acute severe mitral regurgitation due to papillary muscle rupture. Why is the posteromedial papillary muscle vastly more vulnerable to rupture than the anterolateral papillary muscle?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Papillary muscles are intraventricular; they do not penetrate the pericardium. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">A) It is anatomically thinner and penetrates directly into the pericardial space.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The posteromedial papillary muscle relies on a SINGLE blood supply (the Posterior Descending Artery, usually from the RCA). If this artery occludes (Inferior MI), the muscle infarcts and can rupture. In contrast, the anterolateral papillary muscle is protected by a DUAL blood supply (LAD and LCx). Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">B) It relies entirely on a single blood supply (the Posterior Descending Artery), whereas the anterolateral muscle has dual supply.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"It anchors the mitral valve, not the tricuspid valve. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">C) It is responsible for anchoring both the mitral and tricuspid valve leaflets simultaneously.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"It lacks dual supply, which makes it MORE vulnerable, not less. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">D) It receives collateral blood flow directly from the Thebesian veins which are easily occluded by high pressure.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          To meet the strict diagnostic criteria for Peripartum Cardiomyopathy (PPCM), the onset of heart failure (LVEF &lt; 45%) must occur during which precise temporal window?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Heart failure in the first trimester is almost certainly pre-existing dilated cardiomyopathy, not PPCM. Reference: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.\">A) Anytime from the first trimester up to 1 year postpartum.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This timeframe defines late postpartum presentations but excludes the peripartum onset. Reference: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.\">B) Strictly between 1 week postpartum and 6 months postpartum.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The classic diagnostic criteria for PPCM require the development of heart failure toward the end of pregnancy (typically the last month) or within the first 5 months following delivery, in the absence of another identifiable cause. Reference: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.\">C) Within the last month of pregnancy or up to 5 months postpartum.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"PPCM often develops postpartum, not strictly intrapartum. Reference: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.\">D) Strictly during active labor (intrapartum) up to 48 hours post-delivery.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a patient undergoing cardiac catheterization for suspected Constrictive Pericarditis, analysis of the Right Ventricular pressure tracing reveals the classic &#8220;Square Root Sign&#8221;. What does this specific hemodynamic waveform represent?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The 'Square Root Sign' (or dip-and-plateau) occurs in Constrictive Pericarditis. During early diastole, blood rushes into the ventricle rapidly (the 'dip'), but filling is suddenly halted mid-diastole as the ventricle hits the rigid, fibrotic pericardium. The pressure then stays abruptly elevated and flat for the remainder of diastole (the 'plateau'). Reference: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention.\">A) An early diastolic dip in pressure followed by a rapid rise and a flat plateau during mid-to-late diastole.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes a gradual pressure rise typical of normal physiology or heart failure, not constriction. Reference: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention.\">B) A gradual, continuous rise in pressure throughout the entirety of diastole without a plateau.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Tamponade blunts the y-descent; there is no early rapid filling dip. Reference: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention.\">C) A complete absence of the early diastolic pressure dip, yielding a flat line.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes systolic mechanics (e.g., dynamic LVOT obstruction), not diastolic constriction. Reference: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention.\">D) A systolic pressure spike followed by an immediate mid-systolic pressure drop.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Kussmaul&#8217;s sign (the paradoxical rise or failure to fall of the Jugular Venous Pressure during inspiration) is a classic physical finding in Constrictive Pericarditis and RV Infarction. Why is Kussmaul&#8217;s sign typically ABSENT in uncomplicated Cardiac Tamponade?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Tamponade causes high right-sided pressures. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">A) Because tamponade reduces right-sided pressures so profoundly that neck veins collapse entirely.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In tamponade, the pericardium is tense but still transmits intrathoracic pressure changes to the right heart. During inspiration, intrathoracic pressure drops, and this drop IS transmitted to the right heart, allowing increased venous return and the JVP falls normally. In constriction, the thick fibrotic shell shields the heart from intrathoracic pressure drops, so inspiratory venous return piles up in the neck (Kussmaul's sign). Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">B) Because the tense fluid sac in tamponade still transmits negative inspiratory intrathoracic pressure to the right heart.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A thickened shell describes constriction (where Kussmaul's is present), not tamponade. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">C) Because tamponade creates a thick, calcified shell that blocks venous return completely.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Tamponade preserves right heart contractility; it restricts filling. Reference: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases.\">D) Because the right ventricle becomes hyperdynamic in tamponade, aggressively clearing all venous return.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Mineralocorticoid Receptor Antagonists (MRAs) are indicated in symptomatic HFrEF. A male patient taking Spironolactone develops painful gynecomastia and requests an alternative. Why is Eplerenone the preferred substitution?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Both drugs retain potassium; Eplerenone is not a loop diuretic. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">A) Eplerenone does not retain potassium, eliminating the risk of hyperkalemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Spironolactone is non-selective and binds to androgen and progesterone receptors, leading to anti-androgenic side effects like gynecomastia, impotence, and menstrual irregularities. Eplerenone is a highly selective MRA with minimal affinity for sex hormone receptors, greatly reducing these side effects while maintaining cardiovascular benefit. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">B) Eplerenone is highly selective for the mineralocorticoid receptor with minimal affinity for androgen and progesterone receptors.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Both drugs act on the collecting duct. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">C) Eplerenone bypasses the kidney entirely, acting directly as an antifibrotic in the myocardium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Gynecomastia is a receptor-mediated side effect, not a hepatic clearance issue. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">D) Eplerenone is metabolized by the kidney rather than the liver, preventing hepatic testosterone conversion.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When classifying Acute Aortic Dissections to determine management strategy, what is the defining anatomical feature of a Stanford Type A dissection?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This defines a Stanford Type B dissection. Reference: 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases.\">A) It involves only the descending aorta, distal to the left subclavian artery.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The Stanford classification relies entirely on whether the Ascending Aorta is involved. A Type A dissection INVOLVES the ascending aorta (regardless of the site of the primary tear or distal extension) and is a surgical emergency due to the risk of rupture, tamponade, and coronary occlusion. Type B involves only the descending aorta and is usually managed medically. Reference: 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases.\">B) It involves the ascending aorta, regardless of the site of the primary intimal tear.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Extension below the diaphragm does not define Type A versus Type B. Reference: 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases.\">C) It extends below the diaphragm to involve the renal arteries.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Aortic regurgitation is a consequence, but the anatomical involvement of the ascending aorta defines the classification. Reference: 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases.\">D) It must cause acute, severe aortic regurgitation to be classified as Type A.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          During physical examination of a patient with Hypertrophic Obstructive Cardiomyopathy (HOCM), a harsh systolic crescendo-decrescendo murmur is auscultated. How does the Valsalva maneuver affect the intensity of this murmur?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Valsalva decreases preload, which worsens obstruction and INCREASES the murmur. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">A) It DECREASES the intensity of the murmur by reducing preload.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The strain phase of the Valsalva maneuver decreases venous return (reduces LV preload). This causes the LV cavity to become smaller, which brings the anterior mitral leaflet closer to the hypertrophied septum, worsening the dynamic LVOT obstruction. Therefore, the murmur INCREASES in intensity. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">B) It INCREASES the intensity of the murmur by reducing left ventricular preload.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Valsalva predominantly decreases preload, not primarily increasing afterload. Handgrip increases afterload (which decreases the HOCM murmur). Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">C) It DECREASES the intensity of the murmur by increasing afterload.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Valsalva reliably changes the murmur intensity in obstructive HOCM. Reference: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.\">D) It has no effect on the murmur intensity.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-rose-950 text-red-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-rose-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Lipoprotein(a) is recognized as an independent, causal, genetic risk factor for both atherosclerotic cardiovascular disease and calcific aortic valve stenosis. To which coagulation protein is the unique apolipoprotein(a) component structurally homologous, potentially explaining its pro-thrombotic properties?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Fibrinogen is the precursor to fibrin, not structurally homologous to Lp(a). Reference: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias.\">A) Fibrinogen.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Thrombin cleaves fibrinogen, but is not homologous to Lp(a). Reference: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias.\">B) Thrombin (Factor IIa).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The apolipoprotein(a) tail of Lipoprotein(a) contains multiple 'kringle' domains that are highly homologous to Plasminogen. Because of this structural similarity, Lp(a) can competitively inhibit plasminogen binding, thereby impairing fibrinolysis and promoting a pro-thrombotic state. Reference: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias.\">C) Plasminogen.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Antithrombin III is a natural anticoagulant, not homologous to Lp(a). Reference: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias.\">D) Antithrombin III.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq20Correct = 0;\n  let mcq20Answered = 0;\n  const mcq20Total = 25;\n\n  document.querySelectorAll('#mcq20-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq20Answered++;\n\n        document.getElementById('mcq20-answered-count').innerText = mcq20Answered;\n        const pct = (mcq20Answered \/ mcq20Total) * 100;\n        document.getElementById('mcq20-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq20Correct++;\n          document.getElementById('mcq20-correct-count').innerText = mcq20Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-emerald-950\/80', 'border-emerald-500', 'text-emerald-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-rose-950\/80', 'border-rose-500', 'text-rose-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-emerald-950\/40', 'border-emerald-500\/55', 'text-emerald-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-emerald-400' : 'text-rose-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-emerald-950\/45' : 'bg-rose-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-emerald-500\/30' : 'border-rose-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>\ud83c\udfc6 Advanced Cardiology Series &#8211; Milestone Part 20 Interactive Cardiology MCQs #20 Post-Graduate Level Clinical, Hemodynamics, EP &amp; Structural Masterclass \ud83c\udfaf Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 When evaluating the severity of Mitral Regurgitation (MR) via color flow Doppler echocardiography, what measurement of the vena contracta width is the standard cutoff indicative of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68016,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68015","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\ud83c\udfc6 Advanced Cardiology Series &#8211; Milestone Part 20 Interactive Cardiology MCQs #20 Post-Graduate Level Clinical, Hemodynamics, EP &amp; Structural Masterclass \ud83c\udfaf Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 When evaluating the severity of Mitral Regurgitation (MR) via color flow Doppler echocardiography, what measurement of the vena contracta width is the standard cutoff indicative of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-01T13:18:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-01T13:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1208\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"New Series of Interactive Cardiology MCQs 20\",\"datePublished\":\"2026-11-01T13:18:47+00:00\",\"dateModified\":\"2026-11-01T13:18:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/\"},\"wordCount\":1905,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/\",\"name\":\"New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg\",\"datePublished\":\"2026-11-01T13:18:47+00:00\",\"dateModified\":\"2026-11-01T13:18:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg\",\"width\":1208,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Series of Interactive Cardiology MCQs 20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/","og_locale":"en_US","og_type":"article","og_title":"New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders","og_description":"\ud83c\udfc6 Advanced Cardiology Series &#8211; Milestone Part 20 Interactive Cardiology MCQs #20 Post-Graduate Level Clinical, Hemodynamics, EP &amp; Structural Masterclass \ud83c\udfaf Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 When evaluating the severity of Mitral Regurgitation (MR) via color flow Doppler echocardiography, what measurement of the vena contracta width is the standard cutoff indicative of [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-11-01T13:18:47+00:00","article_modified_time":"2026-11-01T13:18:49+00:00","og_image":[{"width":1208,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"New Series of Interactive Cardiology MCQs 20","datePublished":"2026-11-01T13:18:47+00:00","dateModified":"2026-11-01T13:18:49+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/"},"wordCount":1905,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/","url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/","name":"New Series of Interactive Cardiology MCQs 20 - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg","datePublished":"2026-11-01T13:18:47+00:00","dateModified":"2026-11-01T13:18:49+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/New-Series-of-Interactive-Cardiology-MCQs-20.jpg","width":1208,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"New Series of Interactive Cardiology MCQs 20"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68015"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68015\/revisions"}],"predecessor-version":[{"id":68017,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68015\/revisions\/68017"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68016"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}